215 related articles for article (PubMed ID: 32739496)
1. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
Li Q; Lin J; Lin Y
Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
[TBL] [Abstract][Full Text] [Related]
2. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
3. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
4. Paradigms for adaptive statistical information designs: practical experiences and strategies.
Wang SJ; Hung HM; O'Neill R
Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
Cerqueira FP; Jesus AMC; Cotrim MD
Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
[TBL] [Abstract][Full Text] [Related]
6. An adaptive seamless Phase 2-3 design with multiple endpoints.
Jin M; Zhang P
Stat Methods Med Res; 2021 Apr; 30(4):1143-1151. PubMed ID: 33588655
[TBL] [Abstract][Full Text] [Related]
7. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
Sato A; Shimura M; Gosho M
J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
[TBL] [Abstract][Full Text] [Related]
8. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
Schmidli H; Bretz F; Racine A; Maurer W
Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
[TBL] [Abstract][Full Text] [Related]
9. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study.
Connor JT; Broglio KR; Durkalski V; Meurer WJ; Johnston KC
Trials; 2015 Mar; 16():72. PubMed ID: 25885963
[TBL] [Abstract][Full Text] [Related]
10. Interim decision making in seamless trial designs: An application in an adaptive dose-finding study in a rare kidney disease.
Papachristofi O; Bornkamp B; Wright M; Friede T
Pharm Stat; 2024; 23(1):20-30. PubMed ID: 37691560
[TBL] [Abstract][Full Text] [Related]
11. Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R.
Friede T; Stallard N; Parsons N
Biom J; 2020 Sep; 62(5):1264-1283. PubMed ID: 32118317
[TBL] [Abstract][Full Text] [Related]
12. An objective re-evaluation of adaptive sample size re-estimation: commentary on 'Twenty-five years of confirmatory adaptive designs'.
Mehta C; Liu L
Stat Med; 2016 Feb; 35(3):350-8. PubMed ID: 26757953
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
Yoo W; Kim S; Garcia M; Mehta S; Sanai N
BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
[TBL] [Abstract][Full Text] [Related]
14. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
Mauer M; Collette L; Bogaerts J;
Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Clinical Trials: Overview of Phase III Designs and Challenges.
Maca J; Dragalin V; Gallo P
Ther Innov Regul Sci; 2014 Jan; 48(1):31-40. PubMed ID: 30231417
[TBL] [Abstract][Full Text] [Related]
16. Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS).
Teng Z; Liang L; Liu G; Liu Y
Stat Med; 2018 Dec; 37(28):4097-4113. PubMed ID: 30084110
[TBL] [Abstract][Full Text] [Related]
17. Flexible seamless 2-in-1 design with sample size adaptation.
Li R; Wu L; Liu R; Lin J
J Biopharm Stat; 2024 Mar; ():1-19. PubMed ID: 38549502
[TBL] [Abstract][Full Text] [Related]
18. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
Bretz F; Schmidli H; König F; Racine A; Maurer W
Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
[TBL] [Abstract][Full Text] [Related]
19. A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
Chen C; Anderson K; Mehrotra DV; Rubin EH; Tse A
Contemp Clin Trials; 2018 Jan; 64():238-242. PubMed ID: 28966137
[TBL] [Abstract][Full Text] [Related]
20. Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.
Feld J; Faldum A; Schmidt R
Stat Methods Med Res; 2021 Dec; 30(12):2562-2581. PubMed ID: 34641702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
